‘s (178) study revealed that the combination of FAP-targeted radiopharmaceutics [177Lu] Lu-DOTAGA.(SA.FAPi)2 and AMD3100 significantly inhibited cell proliferation, migration and colony formation in triple-negative breast cancer cells, and showed synergistic effects on the 4T1 tumor models, while reducing the number of bone marrow-derived suppressor cells. This evidence concerns the gene FAP and neoplasm.